NO20021520D0 - Substituerte pyridiner og pyridaziner med angiogeneseinhiberende aktivitet - Google Patents

Substituerte pyridiner og pyridaziner med angiogeneseinhiberende aktivitet

Info

Publication number
NO20021520D0
NO20021520D0 NO20021520A NO20021520A NO20021520D0 NO 20021520 D0 NO20021520 D0 NO 20021520D0 NO 20021520 A NO20021520 A NO 20021520A NO 20021520 A NO20021520 A NO 20021520A NO 20021520 D0 NO20021520 D0 NO 20021520D0
Authority
NO
Norway
Prior art keywords
pyridazines
inhibitory activity
substituted pyridines
angiogenesis inhibitory
angiogenesis
Prior art date
Application number
NO20021520A
Other languages
English (en)
Other versions
NO20021520L (no
Inventor
Jacques P Dumas
Stephen James Boyer
Julie A Dixon
Teddy Kite Joe
Harold C E Kluender
Wendy Lee
Dhanapalan Nagarathnam
Robert N Sibley
Ning Su
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO20021520D0 publication Critical patent/NO20021520D0/no
Publication of NO20021520L publication Critical patent/NO20021520L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
NO20021520A 1999-09-28 2002-03-26 Substituerte pyridiner og pyridaziner med angiogeneseinhiberende aktivitet NO20021520L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40760099A 1999-09-28 1999-09-28
PCT/US2000/026500 WO2001023375A2 (en) 1999-09-28 2000-09-26 Substituted pyridines and pyridazines with angiogenesis inhibiting activity

Publications (2)

Publication Number Publication Date
NO20021520D0 true NO20021520D0 (no) 2002-03-26
NO20021520L NO20021520L (no) 2002-05-23

Family

ID=23612752

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021520A NO20021520L (no) 1999-09-28 2002-03-26 Substituerte pyridiner og pyridaziner med angiogeneseinhiberende aktivitet

Country Status (36)

Country Link
EP (1) EP1228063B1 (no)
JP (1) JP4919567B2 (no)
KR (3) KR100890473B1 (no)
CN (3) CN100422172C (no)
AR (3) AR025752A1 (no)
AT (1) ATE422494T1 (no)
AU (1) AU782820B2 (no)
BG (1) BG65860B1 (no)
BR (1) BRPI0014382B8 (no)
CA (1) CA2385817C (no)
CO (1) CO5200835A1 (no)
CZ (1) CZ304767B6 (no)
DE (1) DE60041548D1 (no)
DO (1) DOP2000000070A (no)
EE (1) EE05258B1 (no)
ES (1) ES2320525T3 (no)
GT (1) GT200000158A (no)
HK (2) HK1091819A1 (no)
HR (1) HRP20020308A2 (no)
HU (1) HU230223B1 (no)
IL (3) IL148880A0 (no)
MA (1) MA25563A1 (no)
MX (1) MXPA02003156A (no)
MY (3) MY135058A (no)
NO (1) NO20021520L (no)
NZ (1) NZ518589A (no)
PA (1) PA8503201A1 (no)
PE (1) PE20010607A1 (no)
PL (1) PL205957B1 (no)
RS (1) RS50369B (no)
RU (1) RU2260008C2 (no)
SK (1) SK287417B6 (no)
TW (1) TW593315B (no)
UA (1) UA75053C2 (no)
WO (1) WO2001023375A2 (no)
ZA (1) ZA200202760B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03000874A (es) * 2000-08-09 2003-06-06 Astrazeneca Ab Compuestos quimicos.
DE60134679D1 (de) 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
WO2003059354A2 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
CA2518530A1 (en) * 2003-03-11 2004-09-23 Novartis Ag Use of isoquinoline derivatives for treating cancer and map kinase related diseases
JPWO2004089412A1 (ja) * 2003-04-08 2006-07-06 三菱ウェルファーマ株式会社 特異的ｎａｄ（ｐ）ｈオキシダーゼ抑制剤
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
KR100553398B1 (ko) * 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
WO2006030947A1 (ja) 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
EP2010173A1 (en) * 2006-04-15 2009-01-07 Bayer HealthCare AG Compounds for treating pulmonary hypertension
ES2556173T3 (es) 2006-05-18 2016-01-13 Eisai R&D Management Co., Ltd. Agente antitumoral para un cáncer de tiroides
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
CN101481380B (zh) * 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
WO2012144463A1 (ja) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
KR102204279B1 (ko) 2013-05-14 2021-01-15 에자이 알앤드디 매니지먼트 가부시키가이샤 자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지
CN103396361B (zh) * 2013-07-24 2016-05-04 中国人民解放军第二军医大学 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用
RS63559B1 (sr) 2014-08-28 2022-10-31 Eisai R&D Man Co Ltd Derivat hinolina velike čistoće i postupak za njegovu proizvodnju
PL3263106T3 (pl) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Sposób tłumienia goryczy pochodnej chinoliny
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
CN104804008B (zh) * 2015-03-27 2016-03-23 亿腾药业（泰州）有限公司 一种工业化生产甲磺酸特拉替尼的方法
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
CN107129502B (zh) * 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315 Mod.I晶型化合物及其制备方法
CN112830932B (zh) * 2020-12-25 2022-04-08 泰州亿腾景昂药业股份有限公司 特拉替尼的游离碱晶型及其制备方法与用途
WO2023081923A1 (en) 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1453897A (fr) * 1965-06-16 1966-07-22 Dérivés du thiophène et de thiéno pyridazines
GB1094044A (en) * 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
FR1516777A (fr) * 1966-08-02 1968-02-05 Innothera Lab Sa Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
ATE267174T1 (de) * 1994-08-09 2004-06-15 Eisai Co Ltd Kondensierte pyridazinverbindungen
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
JP4516690B2 (ja) * 1998-08-11 2010-08-04 ノバルティス アーゲー 血管形成阻害活性を有するイソキノリン誘導体
ES2265929T3 (es) * 1999-03-30 2007-03-01 Novartis Ag Derivados de ftalazina para el tratamiento de enfermedades inflamatorias.
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
WO2001058899A1 (en) * 2000-02-09 2001-08-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase

Also Published As

Publication number Publication date
RU2260008C2 (ru) 2005-09-10
ES2320525T3 (es) 2009-05-25
HRP20020308B1 (no) 2013-01-31
HRP20020308A2 (en) 2004-06-30
GT200000158A (es) 2002-03-16
CN100422172C (zh) 2008-10-01
MXPA02003156A (es) 2002-09-30
KR20020038775A (ko) 2002-05-23
BG106637A (bg) 2003-02-28
JP4919567B2 (ja) 2012-04-18
PL205957B1 (pl) 2010-06-30
AU1569601A (en) 2001-04-30
CN1420879A (zh) 2003-05-28
BG65860B1 (bg) 2010-03-31
AR082231A2 (es) 2012-11-21
DE60041548D1 (de) 2009-03-26
AR025752A1 (es) 2002-12-11
YU22902A (sh) 2004-12-31
SK5912002A3 (en) 2003-01-09
PA8503201A1 (es) 2002-08-26
HK1091818A1 (en) 2007-01-26
BR0014382A (pt) 2003-06-24
IL193367A0 (en) 2009-02-11
HUP0202704A2 (hu) 2002-12-28
IL193368A (en) 2011-05-31
CN1769282A (zh) 2006-05-10
EP1228063A2 (en) 2002-08-07
CO5200835A1 (es) 2002-09-27
EE200200161A (et) 2003-08-15
MY135058A (en) 2008-01-31
SK287417B6 (sk) 2010-09-07
CA2385817A1 (en) 2001-04-05
RS50369B (sr) 2009-11-10
UA75053C2 (en) 2006-03-15
KR20080086547A (ko) 2008-09-25
IL148880A0 (en) 2002-09-12
CZ304767B6 (cs) 2014-10-08
BR0014382B1 (pt) 2014-04-01
KR20080091505A (ko) 2008-10-13
HU230223B1 (en) 2015-10-28
CZ20021444A3 (cs) 2002-08-14
DOP2000000070A (es) 2002-02-28
MY143580A (en) 2011-05-31
EP1228063B1 (en) 2009-02-11
ZA200202760B (en) 2003-10-29
NO20021520L (no) 2002-05-23
BRPI0014382B8 (pt) 2021-05-25
IL193368A0 (en) 2009-02-11
MA25563A1 (fr) 2002-10-01
TW593315B (en) 2004-06-21
PL366342A1 (en) 2005-01-24
HUP0202704A3 (en) 2003-12-29
AU782820B2 (en) 2005-09-01
JP2003526632A (ja) 2003-09-09
NZ518589A (en) 2005-03-24
KR100895571B1 (ko) 2009-04-29
PE20010607A1 (es) 2001-07-12
KR100895572B1 (ko) 2009-04-29
KR100890473B1 (ko) 2009-03-26
CN1769283A (zh) 2006-05-10
HK1091819A1 (en) 2007-01-26
WO2001023375A3 (en) 2002-05-02
ATE422494T1 (de) 2009-02-15
MY143377A (en) 2011-05-13
WO2001023375A2 (en) 2001-04-05
EE05258B1 (et) 2010-02-15
CN100374435C (zh) 2008-03-12
CA2385817C (en) 2010-05-04
AR082232A2 (es) 2012-11-21
CN100422173C (zh) 2008-10-01
IL193367A (en) 2011-03-31

Similar Documents

Publication Publication Date Title
NO20021520L (no) Substituerte pyridiner og pyridaziner med angiogeneseinhiberende aktivitet
DK0970070T3 (da) Phthalaziner med angiogenesis-hæmmende aktivitet
HRP20030306A2 (en) Pyridine derivatives with ikb-kinase (ikk-?) inhibiting activity
EP1240160A4 (en) SUBSTITUTED PYRIDAZINE WITH CYTOKIN INHIBITING ACTIVITY
NO20021449L (no) Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og deres anvendelse
NO20014560D0 (no) Quinasoliner og terapautisk anvendelse derav
NO20030625L (no) Kinolinderivater med VEGF-inhiberende aktivitet
DE60005810D1 (de) Fussstütze und möbelstück
IS6411A (is) Kaspasa tálmar og notkun þeirra
ID29829A (id) Epotilon termodifikasi pada c-21
DK1177178T3 (da) Heterocyclisk substituerede benzimidazoler, deres fremstilling og anvendelse
MA26774A1 (fr) Derives de pyridinyl et de phenyl
NO20020569L (no) Substituerte pyridaziner og kondenserte pyridaziner med angiogeneseinhiberende aktivitet
DK1161434T3 (da) Pyridopyranoazepinderivater, deres fremstilling og terapeutiske anvendelse
DK1106607T3 (da) Uracilforbindelser og anvendelse deraf
DK1043307T3 (da) 3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
DE10163359B4 (de) Pyridinderivat und dessen Komplex
PT1178981E (pt) 3-piridil-4-arilpirrois substituidos e metodos terapeuticos e profilacticos
DK1226137T3 (da) Phenyl- og pyridyltetrahydro-pyridiner med en hæmmende virkning på TNF
ATE280753T1 (de) Hydrazid und alkoxyamid angiogeneseinhibitoren
ZA200500863B (en) Condensed pyridines and pyrimidines with Tie2 (tek) activity.
NO20022482D0 (no) 2-arylkinolinderivater, fremgangsmåte og terapeutisk anvendelse derav
IT1311964B1 (it) Struttura componibile per arredi domestici ed elementi divisori.
DK1127274T3 (da) Detektor og deres anvendelse